GB201704965D0 - Pharmaceutical compounds - Google Patents
Pharmaceutical compoundsInfo
- Publication number
- GB201704965D0 GB201704965D0 GBGB1704965.1A GB201704965A GB201704965D0 GB 201704965 D0 GB201704965 D0 GB 201704965D0 GB 201704965 A GB201704965 A GB 201704965A GB 201704965 D0 GB201704965 D0 GB 201704965D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- pharmaceutical compounds
- pharmaceutical
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1704965.1A GB201704965D0 (en) | 2017-03-28 | 2017-03-28 | Pharmaceutical compounds |
| PCT/GB2018/050845 WO2018178691A1 (en) | 2017-03-28 | 2018-03-28 | Isoindolinone inhibitors of the mdm2-p53 interaction and process for making them |
| KR1020197030377A KR102673967B1 (ko) | 2017-03-28 | 2018-03-28 | Mdm2-p53 상호작용의 아이소인돌린온 저해제 및 이를 제조하는 방법 |
| CN201880022720.4A CN110678462B (zh) | 2017-03-28 | 2018-03-28 | Mdm2-p53相互作用的异吲哚啉酮抑制剂和其制造方法 |
| US16/498,207 US11603367B2 (en) | 2017-03-28 | 2018-03-28 | Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them |
| EP18715926.4A EP3601272A1 (en) | 2017-03-28 | 2018-03-28 | Isoindolinone inhibitors of the mdm2-p53 interaction and process for making them |
| JP2019552594A JP7495790B2 (ja) | 2017-03-28 | 2018-03-28 | Ｍｄｍ２－ｐ５３相互作用のイソインドリノン阻害剤およびそれを作製するためのプロセス |
| US18/159,452 US12077526B2 (en) | 2017-03-28 | 2023-01-25 | Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them |
| US18/785,847 US20250074900A1 (en) | 2017-03-28 | 2024-07-26 | Isoindolinone inhibitors of the mdm2-p53 interaction and process for making them |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1704965.1A GB201704965D0 (en) | 2017-03-28 | 2017-03-28 | Pharmaceutical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201704965D0 true GB201704965D0 (en) | 2017-05-10 |
Family
ID=58687834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1704965.1A Ceased GB201704965D0 (en) | 2017-03-28 | 2017-03-28 | Pharmaceutical compounds |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11603367B2 (https=) |
| EP (1) | EP3601272A1 (https=) |
| JP (1) | JP7495790B2 (https=) |
| KR (1) | KR102673967B1 (https=) |
| CN (1) | CN110678462B (https=) |
| GB (1) | GB201704965D0 (https=) |
| WO (1) | WO2018178691A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704965D0 (en) * | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| CN113453678A (zh) * | 2018-11-26 | 2021-09-28 | 德彪药业国际股份公司 | Hiv感染的联合治疗 |
| CN109897069B (zh) * | 2019-02-12 | 2021-08-20 | 华东师范大学 | 一种3，3-二取代吲哚啉酮及其衍生物及其合成方法和应用 |
| CN110845288B (zh) * | 2019-11-28 | 2022-07-19 | 浙江工业大学 | 一种手性β-氨基醛类化合物的不对称合成方法 |
| GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| CN111057128B (zh) * | 2019-12-25 | 2023-05-16 | 哈尔滨师范大学 | 一种含硫的异吲哚酮并环肽衍生物及其制备方法 |
| EP4204812A2 (en) | 2020-08-27 | 2023-07-05 | Otsuka Pharmaceutical Co., Ltd. | Biomarkers for cancer therapy using mdm2 antagonists |
| GB202103080D0 (en) | 2021-03-04 | 2021-04-21 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| TW202540077A (zh) * | 2023-11-16 | 2025-10-16 | 日商大塚製藥股份有限公司 | 具有抗癌活性之ｍｄｍ２－ｐ５３交互作用的異吲哚啉酮抑制劑的中間體的製造方法 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH374071A (de) | 1959-04-30 | 1963-12-31 | Geigy Ag J R | Verfahren zur Herstellung von neuen Isoindolinderivaten |
| US3466298A (en) | 1967-03-14 | 1969-09-09 | American Home Prod | Process for the preparation of 2-(2-aminoethyl)isoindolines |
| US3763178A (en) | 1968-09-05 | 1973-10-02 | American Home Prod | Imidazolinyl phenyl carbonyl acid addition salts and related compounds |
| GB1325066A (en) | 1970-02-12 | 1973-08-01 | American Home Prod | Phthalimidine compounds |
| AR203996A1 (es) | 1972-03-16 | 1975-11-12 | Rhone Poulenc Sa | Procedimiento para preparar derivados de(hidroxi-2-amino-3-propoxi)-3-isoindolinona-1 |
| FR2217000B1 (https=) | 1973-02-08 | 1976-04-09 | Rhone Poulenc Ind | |
| GB1601701A (en) | 1977-07-22 | 1981-11-04 | Delmar Chem | Production of heterocyclic benzamide compounds |
| US4200759A (en) | 1978-07-20 | 1980-04-29 | Delmar Chemicals, Limited | Preparation of imidazo[2,1-a]isoindole compounds |
| US4244966A (en) | 1979-09-24 | 1981-01-13 | American Home Products Corporation | 1,3-Dihydro-3-(2-hydroxy-, 2-bromo- or 2-chloroethyl)-2H-isoindol-1-one derivatives |
| US4331600A (en) | 1980-10-31 | 1982-05-25 | Usv Pharmaceutical Corporation | Intermediates for the synthesis of phthalimidines |
| US4312809A (en) | 1980-10-31 | 1982-01-26 | E. R. Squibb & Sons, Inc. | Lactam derivatives of mercaptoacylamino acids |
| FR2533563A1 (fr) | 1982-09-23 | 1984-03-30 | Adir | Nouveaux derives de la sulfonyluree, leurs procedes de preparation et les compositions pharmaceutiques les renfermant |
| HU212435B (en) | 1990-06-07 | 1996-06-28 | Sandoz Ag | Herbicidal compositions containing substituted phthalides and heterocyclic phthalides as active ingredient and process for preparation of their active ingredients. |
| TW448172B (en) | 1996-03-08 | 2001-08-01 | Pharmacia & Upjohn Co Llc | Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation |
| DE19807423A1 (de) | 1998-02-21 | 1999-08-26 | Hoechst Marion Roussel De Gmbh | Subustituierte Isoindolone, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| CA2380389A1 (en) | 1999-07-26 | 2001-02-01 | Banyu Pharmaceutical Co., Ltd. | Biarylurea derivatives |
| WO2001032928A2 (en) | 1999-11-05 | 2001-05-10 | Phase-1 Molecular Toxicology | Methods of determining individual hypersensitivity to an agent |
| DE10134482A1 (de) | 2001-07-16 | 2003-01-30 | Bayer Ag | Substituierte Isoindole und ihre Verwendung |
| PL370823A1 (en) | 2001-12-18 | 2005-05-30 | F.Hoffmann-La Roche Ag | Cis-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors |
| FR2840302B1 (fr) | 2002-06-03 | 2004-07-16 | Aventis Pharma Sa | Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
| WO2004048332A1 (ja) | 2002-11-26 | 2004-06-10 | Maruishi Pharmaceutical Co., Ltd. | イソインドリン誘導体 |
| JP2004217591A (ja) * | 2003-01-16 | 2004-08-05 | Dai Ichi Seiyaku Co Ltd | シス選択的フルオロシクロプロパン誘導体の製造方法 |
| US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| JP2005255660A (ja) | 2004-03-10 | 2005-09-22 | Katsuhiko Tomooka | 多官能基を有するラクタム類とその製法 |
| WO2005095341A1 (ja) | 2004-03-30 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | 含窒素複素環化合物 |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| GB0419481D0 (en) | 2004-09-02 | 2004-10-06 | Cancer Rec Tech Ltd | Isoindolin-1-one derivatives |
| KR100944301B1 (ko) | 2005-02-22 | 2010-02-24 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Ｍｄｍ２의 소분자 억제제 및 이의 용도 |
| US7705021B2 (en) * | 2005-05-02 | 2010-04-27 | Fox Chase Cancer Center | Isoindolone compounds, compositions containing the same, and methods of use thereof for the treatment of viral infections related to the etiology of cancer |
| JP5031745B2 (ja) | 2005-08-12 | 2012-09-26 | アストラゼネカ アクチボラグ | 代謝型グルタミン酸受容体増強性イソインドロン |
| US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| JPWO2008047831A1 (ja) | 2006-10-17 | 2010-02-25 | 協和発酵キリン株式会社 | Ｊａｋ阻害剤 |
| GB0706072D0 (en) | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
| KR20100033981A (ko) | 2007-06-03 | 2010-03-31 | 벤더르빌트 유니버시티 | 벤즈아미드 대사성 글루타민산염 수용체5 양성 알로스테릭 조절자 및 이의 제조 및 사용방법 |
| GB0811643D0 (en) * | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| DE102008031517A1 (de) * | 2008-07-03 | 2010-01-07 | Merck Patent Gmbh | Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate |
| US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| MY160424A (en) | 2008-09-18 | 2017-03-15 | Hoffmann La Roche | Substituted pyrrolidine-2-carboxyamides. |
| UA107814C2 (uk) | 2009-11-12 | 2015-02-25 | Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган | Спірооксіндольні антагоністи мdм2 |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| SG193002A1 (en) | 2011-03-10 | 2013-09-30 | Daiichi Sankyo Co Ltd | Dispiropyrrolidine derivative |
| US8859586B2 (en) | 2011-06-20 | 2014-10-14 | Novartis Ag | Cyclohexyl isoquinolinone compounds |
| WO2012175520A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
| EP3431142B1 (en) | 2011-08-30 | 2020-06-17 | Astex Pharmaceuticals, Inc. | Decitabine derivative formulations |
| UY34591A (es) | 2012-01-26 | 2013-09-02 | Novartis Ag | Compuestos de imidazopirrolidinona |
| KR101401705B1 (ko) | 2012-01-31 | 2014-06-27 | 울산대학교 산학협력단 | 로듐 촉매를 이용한 이소인돌린 유도체의 합성방법 |
| US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| HRP20200521T1 (hr) | 2012-10-30 | 2020-08-07 | Mei Pharma, Inc. | Kombinacijske terapije za liječenje kemorezistentnih rakova |
| CA2902433A1 (en) | 2013-03-01 | 2014-09-04 | Astex Pharmaceuticals, Inc. | Drug combinations |
| SG11201510816SA (en) | 2013-07-03 | 2016-01-28 | Hoffmann La Roche | Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist |
| US20160333419A1 (en) | 2014-01-14 | 2016-11-17 | Daiichi Sankyo Company, Limited | Gene signatures associated with sensitivity to mdm2 inhibitors |
| CA2945527C (en) | 2014-04-17 | 2022-05-17 | The Regents Of The University Of Michigan | Mdm2 inhibitors and therapeutic methods using the same |
| JP2017532959A (ja) | 2014-10-09 | 2017-11-09 | 第一三共株式会社 | Ｍｄｍ２阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム |
| EP3206697A2 (en) | 2014-10-17 | 2017-08-23 | Biomirna Holdings Ltd. | Lung cancer diagnostics and therapeutics with mir-660 |
| AU2016287585B2 (en) | 2015-07-02 | 2020-12-17 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized pharmaceutical compositions |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| HUE068392T2 (hu) | 2015-10-21 | 2024-12-28 | Otsuka Pharma Co Ltd | Benzolaktám vegyületek mint fehérje kináz gátlók |
| TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
| GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704965D0 (en) * | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| CA3050645A1 (en) | 2018-07-27 | 2020-01-27 | Ottawa Hospital Research Institute | Treatment of acute myeloid leukemia |
| EP3814525A4 (en) | 2019-02-24 | 2022-04-13 | Ascentage Pharma (Suzhou) Co., Ltd. | TREATMENT METHODS AND BIOMARKERS FOR MDM2 INHIBITORS |
| GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| EP4204812A2 (en) | 2020-08-27 | 2023-07-05 | Otsuka Pharmaceutical Co., Ltd. | Biomarkers for cancer therapy using mdm2 antagonists |
| GB202103080D0 (en) | 2021-03-04 | 2021-04-21 | Otsuka Pharma Co Ltd | Cancer biomarkers |
-
2017
- 2017-03-28 GB GBGB1704965.1A patent/GB201704965D0/en not_active Ceased
-
2018
- 2018-03-28 CN CN201880022720.4A patent/CN110678462B/zh active Active
- 2018-03-28 WO PCT/GB2018/050845 patent/WO2018178691A1/en not_active Ceased
- 2018-03-28 EP EP18715926.4A patent/EP3601272A1/en active Pending
- 2018-03-28 JP JP2019552594A patent/JP7495790B2/ja active Active
- 2018-03-28 US US16/498,207 patent/US11603367B2/en active Active
- 2018-03-28 KR KR1020197030377A patent/KR102673967B1/ko active Active
-
2023
- 2023-01-25 US US18/159,452 patent/US12077526B2/en active Active
-
2024
- 2024-07-26 US US18/785,847 patent/US20250074900A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7495790B2 (ja) | 2024-06-05 |
| EP3601272A1 (en) | 2020-02-05 |
| WO2018178691A1 (en) | 2018-10-04 |
| US20230278989A1 (en) | 2023-09-07 |
| KR20190133190A (ko) | 2019-12-02 |
| KR102673967B1 (ko) | 2024-06-12 |
| US11603367B2 (en) | 2023-03-14 |
| CN110678462B (zh) | 2024-10-29 |
| US12077526B2 (en) | 2024-09-03 |
| US20210101887A1 (en) | 2021-04-08 |
| JP2020515546A (ja) | 2020-05-28 |
| CN110678462A (zh) | 2020-01-10 |
| US20250074900A1 (en) | 2025-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266017A (en) | Pharmaceutical compounds | |
| IL258213B (en) | Pharmaceutical compounds | |
| GB201612092D0 (en) | Pharmaceutical compounds | |
| GB201617758D0 (en) | Pharmaceutical compounds | |
| ZA201900540B (en) | Pharmaceutical compounds | |
| GB201504675D0 (en) | Pharmaceutical compounds | |
| GB201506658D0 (en) | Pharmaceutical compounds | |
| GB201519352D0 (en) | Pharmaceutical compounds | |
| EP3638658C0 (en) | PHARMACEUTICAL COMPOUNDS | |
| GB201506660D0 (en) | Pharmaceutical compounds | |
| GB201617454D0 (en) | Pharmaceutical compounds | |
| GB201704714D0 (en) | Pharmaceutical compounds | |
| IL258246A (en) | Pharmaceutical compounds | |
| GB201704965D0 (en) | Pharmaceutical compounds | |
| GB201703881D0 (en) | Pharmaceutical compounds | |
| GB201617627D0 (en) | Pharmaceutical compounds | |
| GB201612095D0 (en) | Pharmaceutical compounds | |
| GB201506933D0 (en) | Pharmaceutical compounds | |
| GB201502567D0 (en) | Pharmaceutical compounds | |
| GB201706806D0 (en) | Pharmaceutical compounds | |
| GB201711704D0 (en) | Pharmaceutical compounds | |
| LT3728220T (lt) | Farmaciniai junginiai | |
| GB201704966D0 (en) | Pharmaceutical compounds | |
| GB201617871D0 (en) | Pharmaceutical compounds | |
| GB201615916D0 (en) | Pharmaceutical compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |